Taipei, Taiwan

Jung-Hsing Lin

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2012-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Jung-Hsing Lin in Neurodegenerative Disease Treatment

Introduction

Jung-Hsing Lin is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of therapeutic agents aimed at preventing and treating neurodegenerative diseases. With a total of 2 patents, his work focuses on innovative solutions that target critical biological pathways.

Latest Patents

One of his latest patents provides therapeutic agents that synergistically target both the adenosine A receptor (AR) and the equilibrative nucleoside transporter 1 (ENT1). This invention holds promise for the treatment of neurodegenerative diseases. Another notable patent describes methods of making and using an adenosine analogue, which includes compounds, extracts, and pharmaceutical compositions for treating metabolic disorders and medical conditions such as Huntington's disease and abnormal blood glucose levels.

Career Highlights

Jung-Hsing Lin is affiliated with Academia Sinica, a leading research institution in Taiwan. His work has garnered attention for its potential impact on the treatment of serious medical conditions. His innovative approaches have positioned him as a key figure in the field of biomedical research.

Collaborations

He has collaborated with notable colleagues, including Yijuang Chern and Yun-Lian Lin, to advance research in his area of expertise. Their combined efforts contribute to the development of effective therapeutic strategies.

Conclusion

Jung-Hsing Lin's contributions to the field of neurodegenerative disease treatment through his innovative patents highlight his role as a leading inventor. His work continues to inspire advancements in medical research and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…